mRNA cancer vaccines show promise — but the technology isn’t perfect #shorts

Moderna is trying to rebrand itself into the cancer space. The technology they're using here is the use of antigens, and there's some issues with it. If the disease is moving faster than the drug, it's not going to work. If we're not dealing with the tumor microenvironment, it isn't going to work. Other immunotherapy techniques, in my clinical opinion, actually may work better by using an immune-centric approach that's based on deep precision and targeting. You build the right medicines on and off label, stimulate the tumor itself to release the information in the body, and the way it naturally normally would so that your immune system can pick up the snapshots and information and give our body's real response instead of a synthetic one.